2.12
-0.04 (-2.08%)
| Previous Close | 2.16 |
| Open | 2.16 |
| Volume | 2,611,106 |
| Avg. Volume (3M) | 9,929,470 |
| Market Cap | 2,083,201,408 |
| Price / Sales | 22.03 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -390.08% |
| Diluted EPS (TTM) | -0.570 |
| Quarterly Revenue Growth (YOY) | 41,192.50% |
| Current Ratio (MRQ) | 2.22 |
| Operating Cash Flow (TTM) | -370.16 M |
| Levered Free Cash Flow (TTM) | -251.77 M |
| Return on Assets (TTM) | -55.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ImmunityBio, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 74.11% |
| % Held by Institutions | 9.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alphacore Capital Llc | 30 Jun 2025 | 2,974,878 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 24.00 (D. Boral Capital, 1,034.75%) | Buy |
| Median | 16.00 (656.50%) | |
| Low | 8.00 (HC Wainwright & Co., 278.25%) | Buy |
| Average | 16.00 (656.50%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.36 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 05 Nov 2025 | 24.00 (1,034.75%) | Buy | 2.15 |
| 08 Sep 2025 | 24.00 (1,034.75%) | Buy | 2.41 | |
| HC Wainwright & Co. | 10 Sep 2025 | 8.00 (278.25%) | Buy | 2.57 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |